Recent advances have improved our ability to treat the acute symptoms of myocardial infarction, but have done little to prevent the chronic complications that arise afterward. New data suggest that targeting the plasminogen activator and matrix metalloproteinase pathways inhibit adaptive and maladaptive changes that follow myocardial infarction. (pages 1135–1142)